151 related articles for article (PubMed ID: 27881029)
1. Pemphigus herpetiformis-type drug reaction caused by erdosteine containing mucolytic in a child.
Akoglu G; Yavuz SO
Cutan Ocul Toxicol; 2017 Sep; 36(3):302-304. PubMed ID: 27881029
[TBL] [Abstract][Full Text] [Related]
2. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
3. [Desmoglein 1-negative, desmoglein 3-positive pemphigus herpetiformis with involvement of oral mucous membranes].
Brod C; Fierlbeck G; Metzler G; Sönnichsen K; Röcken M; Schaller M
J Dtsch Dermatol Ges; 2005 Apr; 3(4):280-2. PubMed ID: 16370478
[TBL] [Abstract][Full Text] [Related]
4. A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Titti G; Lizzio A; Termini C; Negri P; Fazzio S; Mancini C
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):402-7. PubMed ID: 10984014
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunological profiles in 17 Japanese patients with drug-induced pemphigus studied at Kurume University.
Yoshimura K; Ishii N; Hamada T; Abe T; Ono F; Hashikawa K; Fukuda S; Ohyama B; Koga H; Sogame R; Teye K; Ochiai T; Nakajima H; Nakajima K; Iijima S; Kanzaki M; Kojima K; Nagatani T; Fujimoto W; Karashima T; Nakama T; Ohata C; Furumura M; Tsuruta D; Hashimoto T
Br J Dermatol; 2014 Sep; 171(3):544-53. PubMed ID: 24588203
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
7. Pemphigus herpetiformis: from first description until now.
Kasperkiewicz M; Kowalewski C; Jabłońska S
J Am Acad Dermatol; 2014 Apr; 70(4):780-787. PubMed ID: 24472428
[TBL] [Abstract][Full Text] [Related]
8. Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus.
Nagao K; Tanikawa A; Yamamoto N; Amagai M
Clin Exp Dermatol; 2005 Jan; 30(1):43-5. PubMed ID: 15663502
[TBL] [Abstract][Full Text] [Related]
9. Erdosteine: antitussive and anti-inflammatory effects.
Dal Negro RW
Lung; 2008; 186 Suppl 1():S70-3. PubMed ID: 18185958
[TBL] [Abstract][Full Text] [Related]
10. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
11. [ Erdosteine (Mucodox), oral administration].
J Pharm Belg; 2011 Jun; (2):55-6. PubMed ID: 21823444
[No Abstract] [Full Text] [Related]
12. Pemphigus vegetans Neumann type with anti-desmoglein and anti-periplakin autoantibodies.
Cozzani E; Christana K; Mastrogiacomo A; Rampini P; Drosera M; Casu M; Murialdo G; Parodi A
Eur J Dermatol; 2007; 17(6):530-3. PubMed ID: 17951135
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola M; Floriani I; Page CP
Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
[TBL] [Abstract][Full Text] [Related]
14. [Pemphigus herpetiformis following D-penicillamine in a patient with HLA B8].
Weltfriend S; Ingber A; David M; Sandbank M
Hautarzt; 1988 Sep; 39(9):587-8. PubMed ID: 2972666
[TBL] [Abstract][Full Text] [Related]
15. IgG/IgA pemphigus reactive with desmoglein 1 with additional undetermined reactivity with epidermal basement membrane zone.
Kanwar AJ; Vinay K; Saikia UN; Koga H; Teye K; Tsuruta D; Hashimoto T
Indian J Dermatol Venereol Leprol; 2014; 80(1):46-50. PubMed ID: 24448124
[TBL] [Abstract][Full Text] [Related]
16. [D-penicillamine-induced pemphigus: changes in anti-32-2B immunostaining patterns].
Khashoggi M; Machet L; Perrinaud A; Brive D; Machet MC; Maruani A; Vaillant L
Ann Dermatol Venereol; 2013; 140(8-9):531-4. PubMed ID: 24034638
[TBL] [Abstract][Full Text] [Related]
17. Case of pemphigus herpetiformis with immunoglobulin G autoantibodies against desmocollin-3.
Ansai O; Shimomura Y; Fujimoto A; Sakai A; Tsuchida Y; Hayashi R; Shigehara Y; Hama N; Abe R
J Dermatol; 2017 Jan; 44(1):104-105. PubMed ID: 27177601
[No Abstract] [Full Text] [Related]
18. [Pemphigus foliaceus caused by penicillamine].
Zillikens D; Zentner A; Burger M; Hartmann AA; Burg G
Hautarzt; 1993 Mar; 44(3):167-71. PubMed ID: 8463100
[TBL] [Abstract][Full Text] [Related]
19. Recalcitrant pemphigus herpetiformis with high titer of immunoglobulin G antibody to desmoglein 1 and positive IgG antibody to desmocollin 3, elevating thymus and activation-regulated chemokine.
Matsukura S; Takahashi K; Hirokado M; Ikezawa Y; Nakamura K; Fukuda S; Hashimoto T; Ikezawa Z; Aihara M; Kambara T
Int J Dermatol; 2014 Aug; 53(8):1023-6. PubMed ID: 23432082
[No Abstract] [Full Text] [Related]
20. Penicillamine-induced pemphigus foliaceus-like dermatosis. A case with unusual features, successfully treated by plasmapheresis.
Bahmer FA; Bambauer R; Stenger D
Arch Dermatol; 1985 May; 121(5):665-8. PubMed ID: 3158288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
